Development of INRASTES research activities in the framework of the National Research and Technology Strategy for Smart Specialization (MIS 5002559).
COST Action CA17140 entitled "Nano2Clinic: Cancer Nanomedicine - from the bench to the bedside"
COST Action CA19114: Network for Optimized Astatine labeled Radiopharmaceuticals
Dual-targeting iron oxide nanoparticles against bombesin receptors (BNRs) and Prostate Specific Membrane Antigen (PSMA), radiolabeled with Gallium-68, as PET/MRI imaging agents for prostate cancer
